Skip to Main Content

Paper Details

Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.
Br J Haematol
7
2020
Author NameAffiliation
Christopher R CogleCollege of Medicine, University of Florida
Kimberly E HawkinsCollege of Medicine, University of Florida
  • 1 - 2

Datasets

Release 1.2